Hemp Today studies…
Canadian hashish large Canopy Growth says CBD makers using a selected CO2 extraction methodology might owe them licensing charges or compensation.
Canopy made the declare in a patent infringement lawsuit filed this week towards UK-based medical CBD maker GW Pharmaceuticals. The swimsuit might have broad implications for any corporations making each THC and CBD oil. Canada-based Canopy Growth has enterprise in each marijuana and CBD.
“Potentially everybody who does CO2 extraction may be infringing.” Larry Sandell, a Washington-DC patent legal professional, advised Forbes: “I don’t know how much CO2 extraction falls outside the scope of the patent’s claims. This is why people should care.”
News of the lawsuit was first reported by Marijuana Moment Wednesday.
Who’s in danger?
“Unless GW is able to prove that the patent is invalid, that could mean Canopy would have exclusive rights to an extraction process that is widely used across the market, leaving any company that relies on this method at risk of litigation,” in line with Marijuana Moment.
Ontario-based Canopy Growth stated it acquired the U.S. patent when it bought Germany’s C³ Cannabinoid Compound Co. in 2019